Taken together, these data indicate that, at least at 5 weeks after stroke, improved stroke recovery in Empagliflozin treated animals is likely not associated with attenuated post-stroke Iba-1 immunoreactivity. This evidence concerns the gene AIF1 and stroke disorder.